A New Path Forward: The Therapeutic Potential of Next Generation BTK Inhibitors in CLL/SLL
Targeted agents such as Bruton tyrosine kinase (BTK) inhibitors dramatically changed the treatment landscape for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Unfortunately, challenges with tolerance and resistance are pervasive with these agents. Novel highly selective, non-covalent (reversible) BTK inhibitors that may overcome these challenges are undergoing investigation in clinical trials and have the potential to significantly enhance the treatment of CLL/SLL. In early clinical trials, these agents improved overall response rates, irrespective of prior therapy or mutation status.
With the high volume of new clinical trial data related to CLL/SLL, the hematology/oncology team may be challenged to incorporate these new practice-altering therapies into current treatment plans. Ensure that your team is ready to introduce these therapies to best meet the needs of their diverse patients with CLL/SLL.